RCKT vs. NAMS, RNA, AMPH, GLPG, KROS, AMRX, EVO, GPCR, MRVI, and AGIO
Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include NewAmsterdam Pharma (NAMS), Avidity Biosciences (RNA), Amphastar Pharmaceuticals (AMPH), Galapagos (GLPG), Keros Therapeutics (KROS), Amneal Pharmaceuticals (AMRX), Evotec (EVO), Structure Therapeutics (GPCR), Maravai LifeSciences (MRVI), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical preparations" industry.
Rocket Pharmaceuticals (NASDAQ:RCKT) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, community ranking, risk and media sentiment.
In the previous week, Rocket Pharmaceuticals had 16 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 21 mentions for Rocket Pharmaceuticals and 5 mentions for NewAmsterdam Pharma. Rocket Pharmaceuticals' average media sentiment score of 0.47 beat NewAmsterdam Pharma's score of -0.03 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media.
NewAmsterdam Pharma's return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity.
Rocket Pharmaceuticals currently has a consensus price target of $52.13, indicating a potential upside of 129.42%. NewAmsterdam Pharma has a consensus price target of $33.25, indicating a potential upside of 55.16%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than NewAmsterdam Pharma.
NewAmsterdam Pharma has higher revenue and earnings than Rocket Pharmaceuticals.
Rocket Pharmaceuticals has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500.
Rocket Pharmaceuticals received 360 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 72.18% of users gave Rocket Pharmaceuticals an outperform vote.
98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 31.1% of Rocket Pharmaceuticals shares are held by insiders. Comparatively, 2.5% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Rocket Pharmaceuticals beats NewAmsterdam Pharma on 8 of the 14 factors compared between the two stocks.
Get Rocket Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rocket Pharmaceuticals Competitors List
Related Companies and Tools
